Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma

References

• Rabinowitz I. Interaction between statins and rituximab in non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5486; author reply 5486.
   PubMed Web of Science ®Google Scholar
• Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008;5:e64.
   PubMed Web of Science ®Google Scholar
• Flick ED, Chan KA, Bracci PM, Holly EA. Use of nonsteroidal antiinflammatory drugs and non-Hodgkin lymphoma: a population-based case-control study. Am J Epidemiol 2006;164:497–504.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010;16:1695–100.
   PubMed Web of Science ®Google Scholar
• Goldstein MR, Mascitelli L, Pezzetta F. Monoclonal antibody therapy and non-Hodgkin's lymphoma. N Engl J Med 2009;360:192; author reply 193.
   PubMed Web of Science ®Google Scholar
• Pérez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994;199:1209–1215.
   PubMed Web of Science ®Google Scholar
• Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959–968.
   PubMed Web of Science ®Google Scholar
• Jakobisiak M, Golab J. Potential antitumor effects of statins. Int J Oncol 2003;23:1055–1069.
   PubMed Web of Science ®Google Scholar
• Caraglia M, Budillon A, Tagliaferri P, Marra M, Abbruzzese A, Caponigro F. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr Drug Targets 2005;6:301–323.
   PubMed Web of Science ®Google Scholar
• van der Spek E, Bloem AC, van de Donk NW, et al. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 2006;91:542–545.
   PubMed Web of Science ®Google Scholar
• Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184–2192.
   PubMed Web of Science ®Google Scholar
• Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008;100:134–139.
   PubMed Web of Science ®Google Scholar
• Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer 2007;121:1325–1330.
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Gardner JS, Malone KE. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 2004;100:2308–2316.
   PubMed Web of Science ®Google Scholar
• Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol 2003;56:280–285.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Zmuda JM, Lui LY. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 2003;12:749–756.
   PubMed Web of Science ®Google Scholar
• Kochhar R, Khurana V, Bejjanki H. Statins reduce breast cancer risk: a case control study in US female veterans. J Clin Oncol 2005;23(16 Suppl.): Abstract 514.
   Web of Science ®Google Scholar
• Cauley JA, McTiernan A, Rodabough RJ. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 2006;98:700–707.
   PubMed Web of Science ®Google Scholar
• Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007;131:1282–1288.
   PubMed Web of Science ®Google Scholar
• Singal R, Khurana V, Caldito G, Fort C. Statins and prostate cancer risk: a large case-control study in veterans. J Clin Oncol 2005;23(16 Suppl.): Abstract 1004.
   Web of Science ®Google Scholar
• Singh H, Mahmud SM, Turner D, Xue L, Demers AA, Bernstein CN. Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 2009;104:3015–3023.
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Yu O, Miglioretti DL. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16:416–421.
   PubMed Web of Science ®Google Scholar
• Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213–219.
   PubMed Web of Science ®Google Scholar
• Friedman GD, Flick ED, Udaltsova N. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27–36.
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Glynn RJ, Avorn J. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27–33.
   PubMed Web of Science ®Google Scholar
• Friis S, Poulsen AH, Johnsen SP. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005;114:643–647.
   PubMed Web of Science ®Google Scholar
• Boudreau D, Yu O, Buist D, Miglioretti D. Statin use and prostate cancer risk in a large population based setting. Cancer Causes Control 2008;19:767–774.
   PubMed Web of Science ®Google Scholar
• Iwata H, Matsuo K, Hara S, et al. Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci 2006;97:133–138.
   PubMed Web of Science ®Google Scholar
• Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 2004;101:4960–4965.
   PubMed Web of Science ®Google Scholar
• Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010;6:457–470.
   PubMed Web of Science ®Google Scholar
• Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412:211–221.
   PubMed Web of Science ®Google Scholar
• Ben Sahra I, Laurent K, Giuliano S, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010;70:2465–2475.
   PubMed Web of Science ®Google Scholar
• Dubé C, Rostom A, Lewin G, et al. , US Preventive Services Task Force. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 2007;146:365–375.
   PubMed Web of Science ®Google Scholar
• Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603–1613.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs. Cancer Detect Prev 2006;30:99–101.
   PubMedGoogle Scholar
• Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB. Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 2005;16:301–308.
   PubMed Web of Science ®Google Scholar
• Chang ET, Cronin-Fenton DP, Friis S, Hjalgrim H, Sørensen HT, Pedersen L. Aspirin and other nonsteroidal anti-inflammatory drugs in relation to Hodgkin lymphoma risk in northern Denmark. Cancer Epidemiol Biomarkers Prev 2010;19:59–64.
   PubMed Web of Science ®Google Scholar
• Liu SF, Wang H, Li ZJ, et al. Aspirin induces lytic cytotoxicity in Epstein-Barr virus-positive cells. Eur J Pharmacol 2008;589:8–13.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumors of haematopoieitc and lymphoid tissues. LyonIARC2008. pp 262–264.
   Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187–220.
   Google Scholar
• Nowakowski GS, Maurer MJ, Habermann TM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010;28:412–417.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Asai H, Maeda Y, et al. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2010;21:1217–1221.
   PubMed Web of Science ®Google Scholar
• Samaras P, Heider H, Haile SR, et al. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol 2010;89:783–787.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Rabe KG, Kay NE, et al. Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:1233–1240.
   PubMed Web of Science ®Google Scholar